Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Access Pharmaceuticals, a biopharmaceutical company that develops proprietary products for the treatment and supportive care of cancer patients, has signed a distribution agreement with eMAX Health Systems to expand its MuGard distribution.
Subscribe to our email newsletter
MuGard is a novel, ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments.
eMAX Health Systems CEO Julian Casciano said they look forward to provide additional support to ensure favorable MuGard formulary position among US payers, hospitals, and large provider institutions while strengthening its infrastructure, expanding its distribution channels and economic assistance capabilities, and increasing their overall payer outreach.
Access Pharmaceuticals Managed Care and Market Access vice president Anthony Mottola said adding eMAX Health to their reimbursement infrastructure broadens their reach within the third party payer community and expanding their distribution capabilities.
"As we continue executing on our multifaceted reimbursement strategy, we look to eMAX Health to further support programs designed to assess and manage the synergies of physicians, nurses, patient advocacy groups and health benefit payers, while conveying the clinical and economic value MuGard offers," Mottola said.
Access Pharmaceuticals other products include ProLindac for ovarian cancer and Thiarabine for hematological malignancies, which are under on going clinical trials.